# US 8,541,186 B2 · Cancer detection methods and techniques > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,541,186 B2 - Document ID: US8541186B2 - Status: Granted - Kind: B2 - Application number: 12/858,964 - Filed: 2010-08-18 - Published: 2011-02-24 - Granted: 2013-09-24 - Earliest claimed: 2009-02-20 - Assignees: Care Technologies, Inc. - Applicants: Michael Dan Burke - Inventors: Michael Dan Burke - Web page: https://patentgrep.com/patent/US8541186B2 ## CPC - C12Q 1/26: involving oxidoreductase - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - G01N 2333/90245: acting on paired donors with incorporation of molecular oxygen (1.14) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method is provided for detecting and/or measuring the occurrence of an enzyme in the form of CYP1B1 in a patient for the detection of cancer in said patient. The method includes the steps of administering a reporter substrate to a patient; taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate caused as a result of metabolism of the reporter substrate by said enzyme in said patient during said pre-determined period of time. ## Claims ### Claim 1 A method for detecting and/or measuring an occurrence of an enzyme CYP1B1 in a patient, said method comprising the steps of: a) administering a reporter substrate to a patient; b) taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and c) analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate known to be metabolized by CYP1B1 in the human or animal patient, wherein the reporter substrate includes any or any combination of a luteolin, 13C-luteolin, 2H-luteolin, eupatorin or 13C-eupatorin, and the reporter metabolite is 6-hydroxy-luteolin, desmethyleupatorin, formaldehyde and/or carbon dioxide. ### Claim 2 A method for detecting and/or measuring an occurrence of an enzyme CYP1B1 in a patient sample in vitro, said method comprising the step of: analyzing a patient's bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of a reporter substrate known to be metabolized by CYP1B1 in the human or animal patient, wherein the reporter substrate includes any or any combination of a luteolin, 13C-luteolin, 2H-luteolin, eupatorin or 13C-eupatorin, and the reporter metabolite is 6-hydroxy-luteolin, and desmethyleupatorin. ### Claim 3 (depends on 1) A method according to claim 1 wherein the reporter substrate is a naturally derived product. ### Claim 4 (depends on 3) A method according to claim 3 wherein the reporter substrate is a plant derived product. ### Claim 5 (depends on 1) A method according to claim 1 wherein the reporter substrate is bio-synthesized. ### Claim 6 (depends on 1) A method according to claim 1 wherein the reporter substrate is an isotopically labeled feedstock or product. ### Claim 7 (depends on 1) A method according to claim 1 wherein the pre-determined period of time is between 30 minutes and 48 hours. ### Claim 8 (depends on 1) A method according to claim 1 further comprising: measuring a ratio of the reporter substrate to the metabolite of the reporter substrate in the bodily fluid and/or tissue sample in vitro. ### Claim 9 (depends on 1) A method according to claim 1 further comprising: measuring a ratio of a radio isotope or stable isotope labeled reporter substrate or metabolite to a natural or non-isotope labeled reporter substrate or metabolite in the bodily fluid and/or tissue sample in vitro. ### Claim 10 (depends on 1) A method according to claim 1 wherein the bodily fluid and/or tissue sample is any one of or any combination of exhaled patient air, blood, plasma, serum, urine, faeces, semen, saliva, fine needle aspirate, biopsies, or tissue section. ### Claim 11 (depends on 1) A method according to claim 1 further comprising: measuring an amount of enzyme CYP1B1. ### Claim 12 (depends on 1) A method according to claim 1 further comprising: measuring and/or detecting the amount of enzyme CYP1B1, reporter substrate and/or reporter metabolite using immunotandem mass spectrometry (iMALDI). ### Claim 13 (depends on 12) A method according to claim 12 wherein antibodies are added to the bodily fluid and/or tissue sample in vitro prior to or during the analyzing and/or measuring step to isolate and/or concentrate the CYP1B1, reporter substrate and/or reporter metabolite. ### Claim 14 (depends on 13) A method according to claim 13 wherein the antibodies are substantially immobilized on insoluble beads prior to and/or during the analyzing and/or measuring step. ### Claim 15 (depends on 1) A method according to claim 1 further comprising: measuring and/or detecting the amount of enzyme CYP1B1, reporter substrate and/or reporter metabolite using high performance liquid chromatography (hplc). ### Claim 16 (depends on 1) A method according to claim 1 further comprising: measuring the amount of carbon dioxide using a tandem gas chromatograph-isotope selective mass spectrometer. ### Claim 17 (depends on 1) A method according to claim 1 further comprising: measuring and/or detecting the amount of enzyme CYP1B1, reporter substrate and/or reporter metabolite using imaging mass spectrometry. ### Claim 18 (depends on 1) A method according to claim 1 for detecting and/or measuring cancer in a patient.